Yinan Chen, Ph.D.
Affiliations: | 2012 | Molec & Med Pharmacology 0639 | University of California, Los Angeles, Los Angeles, CA |
Area:
Oncology, Molecular BiologyGoogle:
"Yinan Chen"Parents
Sign in to add mentor| Charles Sawyers | grad student | 2012 | UCLA | |
| (Kinase and Hormone Receptor Signaling Networks in Cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Drost J, Karthaus WR, Gao D, et al. (2016) Organoid culture systems for prostate epithelial and cancer tissue. Nature Protocols. 11: 347-58 |
| Robinson D, Van Allen EM, Wu YM, et al. (2015) Integrative clinical genomics of advanced prostate cancer. Cell. 161: 1215-28 |
| Wanjala J, Taylor BS, Chapinski C, et al. (2015) Identifying actionable targets through integrative analyses of GEM model and human prostate cancer genomic profiling. Molecular Cancer Therapeutics. 14: 278-88 |
| Gao D, Vela I, Sboner A, et al. (2014) Organoid cultures derived from patients with advanced prostate cancer. Cell. 159: 176-87 |
| Karthaus WR, Iaquinta PJ, Drost J, et al. (2014) Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell. 159: 163-75 |
| Polkinghorn WR, Parker JS, Lee MX, et al. (2013) Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discovery. 3: 1245-53 |
| Chen Y, Chi P, Rockowitz S, et al. (2013) ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine. 19: 1023-9 |
| Balbas MD, Evans MJ, Hosfield DJ, et al. (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife. 2: e00499 |
| Yoshioka T, Otero J, Chen Y, et al. (2013) β4 Integrin signaling induces expansion of prostate tumor progenitors. The Journal of Clinical Investigation. 123: 682-99 |
| Clegg NJ, Wongvipat J, Joseph JD, et al. (2012) ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research. 72: 1494-503 |